Related content

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?

By Hoaglin David C   Cislo Paul R  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1077-1078

Informa Healthcare

Access to resources Recommend Favorite

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe   Casciano Roman   Malangone Elisabetta   Buonerba Carlo   Sherman Steven   Willet Jacob   Wang Xufang   Liu Zhimei   De Placido Sabino  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1491-1497

Informa Healthcare

Access to resources Recommend Favorite

Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe   Casciano Roman   Malangone Elisabetta   Buonerba Carlo   Sherman Steven   Willet Jacob   Wang Xufang   Liu Zhimei   De Placido Sabino  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1079-1080

Informa Healthcare

Access to resources Recommend Favorite

Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma

By Hou Ming-Mo  

Clinical Drug Investigation, Vol. 30, Iss. 11, 2010-11 ,pp. : 799-804

Adis International

Access to resources Recommend Favorite

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with Everolimus

By Massard Christophe   Fizazi Karim   Gross-Goupil Marine   Escudier Bernard  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 879-881

Springer Publishing Company

Access to resources Recommend Favorite